Antimicrobial prophylaxis in adults

Mayo Clinic Proceedings

Volumn 86, Issue 7, 2011, Pages 686-701

  Enzler, Mark J ^a   Berbari, Elie ^a   Osmon, Douglas R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; BENZATHINE PENICILLIN; BISMUTH SALICYLATE; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; DICLOXACILLIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; FAMCICLOVIR; INFLUENZA VACCINE; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OSELTAMIVIR; PENICILLIN G; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; RIFAMPICIN; RIFAXIMIN; SULTAMICILLIN; TRIMETHOPRIM; UNINDEXED DRUG; VALACICLOVIR; ZANAMIVIR;

ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ASPLENIA; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; BONE INFECTION; BRONCHOSPASM; CELLULITIS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; COST CONTROL; COUGHING; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED HEADACHE; EVENING DOSAGE; EVIDENCE BASED MEDICINE; GENITAL HERPES; HERPES SIMPLEX; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INFECTIOUS ARTHRITIS; INFLUENZA; INFLUENZA A; INFLUENZA B; LUNG FUNCTION; MENINGOCOCCOSIS; NAUSEA; NOSE DISEASE; OPEN FRACTURE; PERIOPERATIVE PERIOD; PERTUSSIS; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROSTHESIS INFECTION; RHEUMATIC FEVER; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; THROAT DISEASE; TRAVELLER DIARRHEA; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; WOUND INFECTION;

EID: 79959785158     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0012     Document Type: Conference Paper

References (141)

1. Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin Proc. 2000;75:98-109. (Pubitemid 30035800)
2. Crabtree TD, Pelletier SJ, Gleason TG, Pruett TL, Sawyer RG. Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am Surg. 1999;65(6):507-511.
3. US Food and Drug Administration (FDA). Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]: tendonitis risk black box warning, 7/8/2008; 2008. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhuman medical products/ucm089652.htm. Accessed May 20, 2011
4. Gerber MA, Baltimore R, Eaton C, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Diseases in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2009;119:1541-1551.
5. Baddour LM. Cellulitis and erysipelas. In: Baron EL, ed. UpToDate; 2008.
6. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:1289-1312.
7. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406. (Pubitemid 41581713)
8. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant S aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e-8-e55.
9. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988;260:2682-2685. (Pubitemid 18261979)
10. Baddour LM, Epstein AE, Erickson CC, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care and Outcomes Research. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458-477.
11. Centers for Disease Control and Prevention (CDC). Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(RR-5):1-10.
12. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(12):1499-1539. (Pubitemid 44910993)
13. Stapleton A, Stamm W. Prevention of urinary tract infection. Infect Dis Clin North Am. 1997;11:719-733. (Pubitemid 27445481)
14. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med. 2001;135:9-16. (Pubitemid 32619278)
15. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol. 1997;157: 935-939. (Pubitemid 27066282)
16. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107.
17. Moran GJ, Talan DA, Abrahamian FM. Antimicrobial prophylaxis for wounds and procedures in the emergency department. Infect Dis Clin North Am. 2008;22:117-143. (Pubitemid 351273542)
18. Endom EE. Initial management of animal and human bites (V.18.3). UpToDate. 2010. http://www.uptodate.com/contents/initial-management-of-animal- and-human-bites?source=search-result&selectedTitle=4%7E150. Accessed May 20, 2011.
19. Goldstein EJC. Bites. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Vol 2. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:3911-3915.
20. Centers for Disease Control and Prevention (CDC). Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Morb Mortal Wkly Rep. 2005;54:1-15.
21. Antiviral drugs for influenza. Med Lett Drugs Ther. 2009;51(1325): 89-92.
22. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-1032.
23. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, doubleblind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea [published correction appears in Ann Intern Med. 2005;143(3):239]. Ann Intern Med. 2005;142(10):805-812.
24. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats [editorial]. J Infect Dis. 2011;203:6-10.
25. Feinstein AR, Wood HF, Epstein JA, Taranta A, Simpson R, Tursky E. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children: results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med. 1959;260:697-702.
26. Jorup-Rönström C, Briotton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987;15(2):105-106. (Pubitemid 17051548)
27. Sjöblom AC, Eriksson B, Jorup-Rönström C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993;21:390-393.
28. Wang Jh, Liu Yc, Cheng Dl, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis. 1997;25:685-689.
29. Baddour LM. Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery. In: Baron EL, ed. UpToDate. October 28, 2010 ed; 2011. http://www.uptodate.com/contents/recurrent-cellulitis-after-saphenous- venectomy-for-coronary-artery-bypass-graft-surgery?source=search- result&selectedTitle =3%7E10. Accessed May 20, 2011.
30. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2005;54 (RR-7):1-10.
31. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am. 2007;21(3):697-710, viii-ix.
32. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106(2, pt 1):362-366.
33. Montalembert M, Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency. Ann Hematol. 2004;83:18-21. (Pubitemid 38088231)
34. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:957-985.
35. Lee BB, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2007;(4):CD003265.
36. Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis. 2004;38:1413-1419. (Pubitemid 38668589)
37. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;(1):CD001321
38. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrotta C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.
39. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753-756. (Pubitemid 23262529)
40. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(9):CD002907.
41. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12:716-724. (Pubitemid 20349256)
42. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology. 1997;25:532-536. (Pubitemid 27106428)
43. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995;22:1171-1174.
44. Singh N, Gayowski T, Yu V, Wagener M. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995;122:595-598.
45. Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;(2):CD004791.
46. Das A. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. Am J Gastroenterol. 1998;93:1895-1900. (Pubitemid 29071701)
47. Baron MJ, Madoff LC. Pancreatic infection. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Vol 1. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:1045-1053.
48. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev. 2010;(5):CD002941.
49. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379-2400.
50. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132(5):2022-2044. (Pubitemid 46677956)
51. Kizer K. Animal bites. In: Gorbach S, Bartlett J, Blacklow N, eds. Infectious Diseases. 2nd ed. Philadelphia, PA: Saunders; 1998:1559-1563.
52. Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJC. Bacteriologic analysis of infected dog and cat bites. N Engl J Med. 1999;340:85-92. (Pubitemid 29054842)
53. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med. 1994;23:535-540. (Pubitemid 24097662)
54. Fleisher GR. The management of bite wounds. N Engl J Med. 1999;340:138-140. (Pubitemid 29054850)
55. Dellinger EP, Wertz MJ, Miller SD, Coyle MB. Hand infections: bacteriology and treatment: a prospective study. Arch Surg. 1988;123:745-750.
56. Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1-34.
57. Centers for Disease Control and Prevention (CDC). Tetanus and pertussis vaccination coverage among adults aged ≥18 years - United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59:1302-1306.
58. Centers for Disease Control and Prevention (CDC). Final 2009 reports of nationally notifiable diseases. MMWR Morb Mortal Wkly Rep. 2010;59:1025, 1035.
59. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:13-15.
60. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Provisional recommendations for health care personnel on use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) and use of postexposure antimicrobial prophylaxis. http://www.cdc.gov/vaccines/recs/provisional/downloads/use-of-Tdap-in-hcp.pdf. Accessed May 20, 2011.
61. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-1754.
62. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-785.
63. Steckelberg JM, Osmon DR. Prosthetic joint infections. In: Waldvogel FA, Bisno AL, eds. Infections Associated With Indwelling Medical Devices. 3rd ed. Washington, DC: American Society for Microbiology; 2000:173-209.
64. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645-1654.
65. Ahlberg A, Carlsson A, Lindberg L. Hematogenous infection in total joint replacement. Clin Orthop Relat Res. 1978;137:69-75. (Pubitemid 9108122)
66. Bengtson S, Blomgren G, Knutson K, Wigren A, Lidgren L. Hemat ogenous infection after knee arthroplasty. Acta Orthop Scand. 1987;58: 529-534. (Pubitemid 18034247)
67. Deacon JM, Pagilaro AJ, Zelicof SB, Horowitz HW. Current concepts review: prophylactic use of antibiotics for procedures after total joint replacement. J Bone Joint Surg Am. 1996;78(11):1755-1770. (Pubitemid 27020628)
68. Uçkay I, Pittet D, Bernard L, Lew D, Perrier A, Peter R. Antibiotic prophylaxis before invasive dental procedures in patients with arthroplasties of the hip and knee. J Bone Joint Surg Br. 2008;90:833-838. (Pubitemid 352009766)
69. Lockhart PB, Loven B, Brennan MT, Fox PC. The evidence base for the efficacy of antibiotic prophylaxis in dental practice. J Am Dent Assoc. 2007;138:458-474.
70. Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis. 2010;50:8-16.
71. Wahl M. Myths of dental-induced prosthetic joint infections. Clin Infect Dis. 1995;20:1420-1425.
72. Lockhart PB, Brennan MT, Fox PC, Norton HJ, Jernigan DB, Strausbaugh LJ. Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review. Clin Infect Dis. 2002;34:1621-1626. (Pubitemid 34615448)
73. Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and after hip arthroplasty. Clin Orthop Relat Res. 1999 Dec;(369):124-138.
74. Little JW. Patients with prosthetic joints: are they at risk when receiving invasive dental procedures? Spec Care Dentist. 1997;17(5):153-160. (Pubitemid 127737928)
75. Sandhu SS, Lowry JC, Reuben SF, Morton ME. Who decides on the need for antibiotic prophylaxis in patients with major arthroplasties requiring dental treatment: is it a joint responsibility? Ann R Coll Surg Engl. 1997;79:143-147. (Pubitemid 27136126)
76. American Dental Association; American Association of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc. 2003;134(7):895-898.
77. American Association of Orthopedic Surgeons (AAOS). Information statement: antibiotic prophylaxis for bacteremia in patients with joint replacements. http://www.aaos.org/about/papers/advistmt/1033.asp. Accessed May 20, 2011.
78. Oliver G, Lowry A, Vernava A, et al; Standards Task Force; American Society of Colon and Rectal Surgeons. Practice parameters for antibiotic prophylaxis - supporting documentation. Dis Colon Rectum. 2000;43(9):1194-1200.
79. ASGE Standards of Practice Committee. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67(6):791-798.
80. American Urological Association; American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for urological patients with total joint replacements. J Urol. 2003;169:1796-1797.
81. Wolf Jr JS, Bennett C, Dmochowski R, Hollenbeck B, Pearle M, Schaeffer A. Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis. Linthicum, MD: American Urological Association; 2007:1-44. http://www.auanet. org/content/media/antimicroprop08.pdf. Accessed May 20, 2011.
82. Aranda-Michel J, Giannella R. Acute diarrhea: a practical review. Am J Med. 1999;106:670-676. (Pubitemid 29279305)
83. Caeiro JP, DuPont HL. Management of travelers' diarrhoea. Drugs. 1998;56(1):73-81.
84. Passaro DJ, Parsonnet J. Advances in the prevention and management of traveler's diarrhea. Curr Clin Top Infect Dis. 1998;18:217-236. (Pubitemid 128646826)
85. Ansdell VE, Ericsson CD. Prevention and empiric treatment of traveler's diarrhea. Med Clin North Am. 1999;83:945-973. (Pubitemid 29356949)
86. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Inf Dis. 2002;34(5):628-633. (Pubitemid 34168207)
87. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am. 1976;58:453-458.
88. Hauser CJ, Adams CA Jr, Eachempath SR. Prophylactic antibiotic use in open fractures: an evidence-based guideline. Surg Infect (Larchmt). 2006;7(4): 379-405. (Pubitemid 46489582)
89. Luchette FA, Bone LB, Born CT, et al; Eastern Association for the Surgery of Trauma (EAST) Working Group. Practice management guidelines for prophylactic antibiotic use in open fractures. Published 1998. Updated in 2009. http://www.east.org/tpg/OpenFxUpdate.pdf. Accessed May 20, 2011.
90. ACOG Committee on Practice Guidelines - Gynecology. Gynecologic Herpes simplex virus infections. Obstet Gynecol. 2004;104(5, pt 1):1111-1 117.
91. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.
92. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999; 341(18):1336-1343. (Pubitemid 29503572)
93. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282(1):31-35. (Pubitemid 29318929)
94. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
95. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60.
96. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993;6(4):428-442. (Pubitemid 23306594)
97. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.
98. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR; Hospital Infection Control Practices Advisory Committee. Guidelines for the prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol. 1999;20(4):250-278.
99. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 1999;56(18):1839-1888.
100. Antimicrobial Prophylaxis for Surgery. Treatment Guidelines from the Medical Letter. 2009 June; 7(82):47-52.
101. Sexton DJ. Carbapenems for surgical prophylaxis [editorial]? N Engl J Med. 2006;355(25):2693-2695.
102. Bratzler DW, Houck PM. Antimicrobial Prophylaxis for Surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706-1715. (Pubitemid 38781662)
103. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery; Part I: duration. Ann Thorac Surg. 2006;81:397-404. (Pubitemid 41815461)
104. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery; Part II: antibiotic choice. Ann Thorac Surg. 2007;83:1569-1576.
105. de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter- defibrillators: results of a large prospective, randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2(1):29-34.
106. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45(2):166-173. (Pubitemid 47041006)
107. Dobay KJ, Freier D, Albear P. The absent role of prophylactic antibiotics in low-risk patients undergoing laparoscopic cholecystectomy. Am Surg. 1999;65(3):226-228. (Pubitemid 29114139)
108. Higgins A, London J, Charland S, et al. Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary? Arch Surg. 1999;134(6): 611-613.
109. Meijer WS, Schmitz PI, Jeekel J. Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg. 1990;77(3):282-290.
110. Baum ML, Anish DS, Chalmers TC, Sacks HS Smith H Jr, Fagerstrom RM. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981;305(14):795- 799. (Pubitemid 11007234)
111. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol. 2009; 113(5):1180-1189.
112. American College of Obstetricians and Gynecologists (ACOG) Committee. Antimicrobial prophylaxis for cesarean delivery: timing of administration: Obstet Gynecol. 2010;116(3):791-792.
113. Simo R, French G. The use of prophylactic antibiotics in head and neck oncological surgery. Curr Opin Otolaryngol Head Neck Surg. 2006;14:55-61.
114. Weber RS. Wound infection in head and neck surgery: implications for perioperative antibiotic treatment. Ear Nose Throat J. 1997;76(11):790-791, 795-798.
115. Barker FG II. Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery. 1994;35(3):484-490.
116. Barker FG II. Efficacy of prophylactic antibiotics in spinal surgery: a meta-analysis. Neurosurgery. 2002;51(2):391-400.
117. Barker FG II. Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery. 2007;60(5):887-894.
118. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. Antimicrobial prophylaxis in neurosurgery and after head injury. Lancet. 1994;344(8936):1547-1551.
119. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis. Neurosurgery. 1994;34(1):87-92.
120. Langley JM, LeBlanc JC, Drake J, Millner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis. 1993;17(1):98-103. (Pubitemid 23197572)
121. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr. 2008;1:48-56. (Pubitemid 351396993)
122. DeCroos FC, Afshari NA. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr Opin Ophthalmol. 2008;19:22-26. (Pubitemid 350307556)
123. Liesegang TJ. Perioperative antibiotic prophylaxis in cataract surgery [published correction appears in Cornea. 2000;19(1):123]. Cornea. 1999;18(4):383-402.
124. Gillespie WJ, Walenkamp G. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. Cochrane Database Syst Rev. 2001;(1): CD000244.
125. Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16:283-293.
126. Homer-Vanniasinkam S. Surgical site and vascular infections: treatment and prophylaxis. Int J Infect Dis. 2007;11(suppl 1):S17-S22. (Pubitemid 46977800)
127. Stewart AH, Eyers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. J Vasc Surg. 2007;46:148-155. (Pubitemid 46990745)
128. Kluytmans JA, Mouton JW, VandenBergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol. 1996; 17(12):780-785. (Pubitemid 126478529)
129. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871-1877. (Pubitemid 34605989)
130. Rey JR, Axon A, Budzynsak A, Kruse A, Nowak A. Guidelines of the European Society of Gastrointestinal Endoscopy (ESGE) antibiotic prophylaxis for gastrointestinal endoscopy. Endoscopy. 1998;30(3):318-324. (Pubitemid 28223118)
131. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AMM, Edixhoven PJ, Spies-van Rooijen NH. Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand. 1998;69:412-414. (Pubitemid 28466573)
132. Centers for Disease Control and Prevention (CDC). Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recom Rep. 1995;44(RR-12):1-13.
133. Centers for Disease Control and Prevention (CDC). Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. 1997;46(27):626-628; 635.
134. Centers for Disease Control and Prevention (CDC). Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(27):624-626.
135. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997 [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46:851]. MMWR Morb Mortal Wkly Rep. 1997;46(33):765-766.
136. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc. 1986;61:721-724. (Pubitemid 16011488)
137. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961;50:161-168.
138. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. N Engl J Med. 1992;326(5):281-286.
139. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis. 2001;7:828-831. (Pubitemid 33121588)
140. Surgical Care Improvement Project (SCIP). QualityNet Web site. http://www.aha.org/aha/issues/Quality-and-Patient-Safety/scip.html. Accessed May 20, 2011.
141. Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol. 2008;59:464-473.